Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-label Study of INNO-206 in Recurrent Extensive Small Cell Lung Cancer
2006-005514-12Phase 2Completed
- Sponsor
- Innovive Pharmaceuticals, Inc.
- Start
- May 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldoxorubicin in small cell lung cancer (SCLC), sponsored by Innovive Pharmaceuticals, Inc. Primary endpoints: Objective overall response rate, Stable disease rate and 1 more. Started May 2007; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-005514-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005514-12.